Effects of intracoronary antithrombotics on ventricular function: A comparison of tenecteplase versus abciximab during primary percutaneous intervention in myocardial infarction

Abstract

Adjunctive medical therapy during primary percutaneous coronary intervention (PPCI) is based on anticoagulation and antiplatelet drugs. Additionally, the glycoprotein IIb/IIIa inhibitor (GPI) abciximab has been shown to reduce infarct size in some clinical trials [1]. However, the role of intracoronary fibrinolysis has not been well established during PPCI. We sought to explore the hypothesis that a locally administered fibrinolytic could be more effective in dissolving coronary thrombus at the macro and microvasculature than adding a third antiplatelet drug in patients already receiving double antiplatelet therapy, and therefore improve myocardial perfusion and left ventricular function.